Background The survival benefit of adjuvant transarterial chemoembolization (TACE) in patients with hepatectomy for hepatocellular carcinoma (HCC) after hepatectomy remains controversial. We aimed to investigate the survival efficacy of adjuvant TACE after hepatectomy for HCC. Methods 1491 patients with HCC who underwent hepatectomy between January 2018 and September 2021 at four medical centers in China were retrospectively analyzed, including 782 patients who received adjuvant TACE and 709 patients who did not receive adjuvant TACE. Propensity score matching (PSM) (1:1) was performed to minimize selection bias, which balanced the clinical characteristics of the two groups. Results A total of 1254 patients were enrolled after PSM, including 627 patients who received adjuvant TACE and 627 patients who did not receive adjuvant TACE. Patients who received adjuvant TACE had higher disease-free survival (DFS, 1- ,2-, and 3-year: 78%-68%-62% vs. 69%-57%-50%, p < 0.001) and overall survival (OS, 1- ,2-, and 3-year: 96%-88%-80% vs. 90%-77%-66%, p < 0.001) than those who did not receive adjuvant TACE (Median DFS was 39 months). Among the different levels of risk factors affecting prognosis [AFP, Lymphocyte-to-monocyte ratio, Maximum tumor diameter, Number of tumors, Child-Pugh classification, Liver cirrhosis, Vascular invasion (imaging), Microvascular invasion, Satellite nodules, Differentiation, Chinese liver cancer stage II-IIIa], the majority of patients who received adjuvant TACE had higher DFS or OS than those who did not receive adjuvant TACE. More patients who received adjuvant TACE accepted subsequent antitumor therapy such as liver transplantation, re-hepatectomy and local ablation after tumor recurrence, while more patients who did not receive adjuvant TACE accepted subsequent antitumor therapy with TACE after tumor recurrence (All p < 0.05). Conclusions Adjuvant TACE may be a potential way to monitor early tumor recurrence and improve postoperative survival in patients with HCC.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

No abstract

No abstract

Background Colon adenocarcinoma (COAD) is a common digestive tract tumor and the molecular mechanism is very complicated. Overexpression of FCHO1 plays the role of oncogene or tumor suppressor gene in the process of tumorigenesis and development. However, possible mechanisms of FCHO1 in COAD remains unknown. Methods Online database Oncomine, TIMER and TCGA were used to clarify the expression level of FCHO1 in COAD. Using receiver operating characteristic (ROC) curve and GEIPA database to evaluate the prognostic value of FCHO1 in COAD. Then, STRING and GeneMANIA database were used to construct the protein-protein interaction network. The GO/KEGG enrichment analysis were performed by Using Funrich. Co-expression genes of FCHO1 were acquired by Linkedomics database, GSEA analysis was used to explore the possible pathway in co-expression genes of FCHO1. The correlation between FCHO1 expression and hypoxia-related genes, glycolysis-related genes and immune infiltrates was analyzed using the TIMER, Starbase and TCGA cohort. Results Our results revealed that high expression level of FCHO1 was significantly increased in COAD tissues than normal tissue. High expression of FCHO1 in COAD predicted worse survival, including OS (HR = 1.8 p = 0.0022), DFS (HR = 1.6 p = 0.043). GSEA analysis showed that co-expression genes were significantly linked with MicroRNAs in cancer, Oxidative phosphorylation, Cell cycle, Notch signaling pathway, VEGF signaling pathway and p53 signaling pathway. Further, the result revealed that hypoxia-related genes (NFKB1, VEGFB) was simultaneously positively correlated with FCHO1 expression in TIMER, Starbase database. Glycolysis-related genes (HK1, G6PD and SLC2A1) was positively associated with FCHO1 expression in TIMER, Starbase database. At the same time, PDCD1 and LAG3 expression, which as immune checkpoint, were positively correlated with FCHO1 expression. Conclusion Collectively, FCHO1 may act as a promising diagnostic and prognostic biomarker and correlated with hypoxia, glycolysis and immune infiltration in COAD.